Novartis (NYSE:NVS) to acquire Anthos Therapeutics for a total deal value of up to $3.1B, consisting of an upfront payment of $925M, with potential additional payments of up to $2.15B.

Feb 11 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's (BX.N), opens new tab drug ...

Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab’s potential to provide superior safety CAMBRIDGE, Mass.

Novartis announced that it has agreed to terms to acquire Anthos Therapeutics for an upfront payment of $925 million. The deal will include abelacimab, a Factor XI-inhibiting monoclonal antibody in ...

Swiss pharmaceutical giant Novartis said on Tuesday (Feb 11) it has agreed to acquire biopharma firm Anthos Therapeutics for up to US$3.1 billion. Anthos was founded by Blackstone Life Sciences and ...

Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for approximately $3.1bn. The deal gives Novartis access to abelacimab, which ...

The acquisition of Anthos Therapeutics and strategic investments in R&D confirmed our thesis on Novartis' new pure play as an innovative medicines leader. Novartis' strong FCF generation ...

Novartis has gone full circle with Anthos Therapeutics. The Swiss pharma giant is doubling down on its expertise in the cardiovascular area by acquiring the clinical-stage biotech firm mostly owned by ...

the development and commercialization of Anthos Therapeutics’ product candidates and the potential benefits of abelacimab. All statements, other than statements of historical facts, contained in ...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...